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MaBACKGROUND Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder with important vascular and
hemostatic alterations that should be taken into account during diagnosis and treatment.
OBJECTIVES This study evaluates whether anticoagulation with dabigatran, a clinically approved oral direct thrombin
inhibitor with a low risk of intracerebral hemorrhage, ameliorates AD pathogenesis in a transgenic mouse model of AD.
METHODS TgCRND8 AD mice and their wild-type littermates were treated for 1 year with dabigatran etexilate or
placebo. Cognition was evaluated using the Barnes maze, and cerebral perfusion was examined by arterial spin labeling.
At the molecular level, Western blot and histochemical analyses were performed to analyze fibrin content, amyloid
burden, neuroinflammatory activity, and blood–brain barrier (BBB) integrity.
RESULTS Anticoagulation with dabigatran prevented memory decline, cerebral hypoperfusion, and toxic fibrin depo-
sition in the AD mouse brain. In addition, long-term dabigatran treatment significantly reduced the extent of amyloid
plaques, oligomers, phagocytic microglia, and infiltrated T cells by 23.7%, 51.8%, 31.3%, and 32.2%, respectively.
Dabigatran anticoagulation also prevented AD-related astrogliosis and pericyte alterations, and maintained expression of
the water channel aquaporin-4 at astrocytic perivascular endfeet of the BBB.
CONCLUSIONS Long-term anticoagulation with dabigatran inhibited thrombin and the formation of occlusive
thrombi in AD; preserved cognition, cerebral perfusion, and BBB function; and ameliorated neuroinflammation and
amyloid deposition in AD mice. Our results open a field for future investigation on whether the use of direct oral
anticoagulants might be of therapeutic value in AD. (J Am Coll Cardiol 2019;74:1910–23) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under
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1911AB BR E V I A T I O N S
AND ACRONYM S
Ab = amyloid-b
AD = Alzheimer’s disease
AQP4 = aquaporin 4
ASL = arterial spin labeling
BBB = blood–brain barrier
CAA = cerebral amyloid
angiopathy
CBF = cerebral blood flow
DOAC = direct oral
anticoagulant
MRI = magnetic resonance
imaging
PDGFRb = platelet-derived
growth factor receptor-bA lzheimer’s disease (AD) is a progressive andmultifactorial neurodegenerative disordercharacterized by amyloid-b (Ab) plaques,
tau tangles, neuroinflammation, and brain atrophy
(1). AD is strongly linked with cardiovascular risk fac-
tors, and is often accompanied by an important
vascular component (2–4). The cerebrovascular pa-
thology present in AD includes blood–brain barrier
(BBB) disruption, neurovascular unit dysfunction,
neurovascular uncoupling, and cerebral blood flow
(CBF) alterations (5–7). Furthermore, chronic dysre-
gulated hemostasis is present in AD, with increased
thrombin generation, presence of activated platelets,
and leakage of plasma proteins into the brain paren-
chyma (8,9), favoring the formation and persistence
of fibrin clots (10,11).SEE PAGE 1924
WB = Western blot
WT = wild typeFibrin(ogen) is up-regulated early in AD (12), is
found intravascularly and extravascularly in areas
of synaptic dysfunction and amyloid pathology
(10,11), and interacts with Ab (13,14) inducing the
formation of resistant clots (10,15). Because
decreasing systemic fibrin(ogen) levels in AD mice
ameliorates disease progression (10,11,16), thera-
peutics that normalize the prothrombotic environ-
ment present in AD might be useful in combination
with other strategies (17). Indeed, traditional anti-
coagulants have been reported to be beneficial for
dementia patients (18,19) and AD mouse models
(20,21). However, to overcome their important lim-
itations, such as the necessity for close monitoring
and the high risk of bleeding, direct oral anticoag-
ulants (DOACs) have emerged as a useful alternative
(22). Among these, dabigatran is a potent oral direct
thrombin inhibitor already approved for several in-
dications, such as the prevention of stroke in pa-
tients with nonvalvular atrial fibrillation and the
treatment of venous thromboembolism (23). Dabi-
gatran has minimal drug–drug interactions (22), a
low risk of intracranial bleeding (24,25), a potent
anti-inflammatory effect (26), and an effective
reversal agent available (27).
Here, we present evidence that long-term anti-
coagulation with dabigatran ameliorates multiple
features of AD pathogenesis. Dabigatran treatment
preserved memory and cerebral perfusion in trans-
genic AD mice, which was accompanied by improved
BBB integrity, together with lower levels of fibrin,
amyloid deposition, and neuroinflammatory activity
in the AD brain.METHODS
MICE. TgCRND8 AD mice and nontransgenic
littermate controls were provided by The
Tanz Centre for Research in Neurodegenera-
tive Diseases, University of Toronto, Canada
(28). Only female mice were used for this
study due to the aggressive behavior of
TgCRND8 male littermates, and single hous-
ing was not feasible for long-term and
behavioral experiments. Seventy female mice
were obtained through in vitro fertilization:
37 TgCRND8 and 33 wild-type (WT) mice. Five
TgCRND8 mice died before weaning, and 8
died during placebo/dabigatran treatment,
which means a 35% loss in TgCRND8 mice, in
line with previous studies (28). Only 1 WT
mouse died during placebo treatment. Pla-
cebo/dabigatran treatment was also con-
ducted in smaller 30-week-old cohorts, and brains
from these mice were extracted and included in the
Western blot (WB) and immunohistochemical ana-
lyses. Group sizes for all experiments are indicated in
each section. Animal protocols were approved by the
corresponding institutional animal care and
use committees.
DABIGATRAN TREATMENT. Two-month-old female
TgCRND8 mice and their nontransgenic WT litter-
mates (n ¼ 13 to 18 mice/group) were randomized into
groups receiving chow supplemented with 5 mg/g of
the prodrug dabigatran etexilate (BIBR 1048) or pla-
cebo (both provided by Boehringer Ingelheim, Ingel-
heim am Rhein, Germany) and were treated until they
were 30 weeks old (30w) (n ¼ 8 to 11 mice/group) or
60 weeks old (60w) (n ¼ 5 to 7 mice/group). Diluted
thrombin time assays were performed to measure
dabigatran plasma concentration (23).
BARNES MAZE. The Barnes maze was used to assess
spatial memory in 25-week-old TgCRND8 mice and
WT littermates treated with dabigatran/placebo for
17 weeks (n ¼ 16 WT/placebo; n ¼ 14 AD/placebo;
n ¼ 16 WT/dabigatran; n ¼ 12 AD/dabigatran mice/
group) as described in the Online Methods.
ARTERIAL SPIN LABELING. CBF was evaluated
noninvasively by arterial spin labeling (ASL)–mag-
netic resonance imaging (MRI) on 40-week-old
TgCRND8 mice and their WT littermates treated with
dabigatran/placebo for 32 weeks (n ¼ 7 WT/placebo,
n ¼ 6 AD/placebo, n ¼ 6 WT/dabigatran, n ¼ 5 AD/
dabigatran mice/group) as described in the
Online Methods.
























































TgCRND8 AD mice and WT littermates (n ¼ 13 to 18 female mice/group) started dabigatran/placebo treatment at 8 weeks of age, and were sacrificed after 22 weeks (at
30 weeks of age [30w], n ¼ 8 to 11 mice/group) or 52 weeks of treatment (at 60 weeks of age [60w], n ¼ 5 to 7 mice/group). Histology and WB assays were performed
in the 8 experimental groups (WT/30w/placebo, AD/30w/placebo, WT/30w/dabigatran, AD/30w/dabigatran, WT/60w/placebo, AD/60w/placebo, WT/60w/dabigatran,
and AD/60w/dabigatran). Blood was extracted before and after treatment to measure dabigatran concentration by diluted thrombin time assays (representative graph
is shown). Barnes maze to assess spatial memory performance was performed 17 weeks after the treatment started (at 25 weeks of age, n ¼ 12 to 16 mice/group).
Cerebral perfusion was measured noninvasively by ASL-MRI 32 weeks after treatment started (at 40 weeks of age, n ¼ 5 to 7 mice/group). AD ¼ Alzheimer’s disease;
ASL ¼ arterial spin labeling; Dab ¼ dabigatran; MRI ¼ magnetic resonance imaging; WB ¼ Western blot; WT ¼ wild type.
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ing) protein fractions were extracted from the cortex
and hippocampus of mice in each experimental group
(n ¼ 8 WT/30w/placebo, n ¼ 9 AD/30w/placebo, n ¼ 10
WT/30w/dabigatran, n ¼ 11 AD/30w/dabigatran, n ¼ 6
WT/60w/placebo, n ¼ 6 AD/60w/placebo, n ¼ 6 WT/
60w/dabigatran, n ¼ 5 AD/60w/dabigatran mice/
group) and subjected to WB analysis as described in
the Online Methods.
MOUSE BRAIN STAINING AND QUANTIFICATION.
Diaminobenzidine immunohistochemical and double
immunofluorescence analyses were performed in
free-floating sections as previously described (29). All
analyses were performed blindly. Experimental group
sizes are the same as described for WB. Details can be
found in the Online Methods.
STATISTICS. All numerical values are shown as mean
 SEM. Graphs, outlier calculations, and statisticswere generated using GraphPad Prism version 8.0.1
software (GraphPad Software, San Diego, California).
Comparison of 2 groups (indicated by a horizontal line
in the corresponding graph) was performed using the
Student’s t-test. To determine whether the effect of
genotype, age, or treatment was significant, 2-way
analyses of variance and Tukey’s post-test for multi-
ple comparisons was performed. Significance is re-
ported as follows: *p # 0.05, **p # 0.01, and,
***p # 0.001.
RESULTS
TgCRND8 female AD mice and their nontransgenic
littermates were fed chow supplemented with dabi-
gatran etexilate or placebo at 8 weeks of age, imme-
diately before amyloid deposition (Figure 1). On the
basis of food ingestion per mouse (w5 g), animal
weights throughout the study (26.5  4.0 g), and the
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TgCRND8 AD mice and WT controls treated with dabigatran/placebo were subjected to
the Barnes maze task to assess spatial memory at 25 weeks of age. (A) Mice were trained
for 7 days, and latency to explore the target hole (nose poke) was measured and plotted.
All groups learned the position of the escape box during training. (B) Time spent near
the escape and adjoining holes (target quadrant) and average time spent near other
holes (nontarget quadrants) during the probe trial were measured and plotted. Placebo-
treated AD mice did not show a preference for the target area, whereas dabigatran-
treated AD mice explored the target region significantly more than the nontarget
locations. Graphs show mean  SEM. *p # 0.05, **p # 0.01 target versus nontarget
quadrants in each experimental group. n ¼ 12 to 16 mice/group. Abbreviations as in
Figure 1.
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1913low bioavailability of dabigatran etexilate (6.5%) (30),
we estimated that mice received an average dose of
w60 mg/kg of dabigatran etexilate over 24 h. Diluted
thrombin time assays showed delayed clot formation
in plasma from dabigatran-treated mice (Figure 1),
and the average active plasma dabigatran concentra-
tion throughout treatment was 141.2  72.5 ng/ml in
the WT/dabigatran group and 125.7  64.5 ng/ml in
the AD/dabigatran group. During dabigatran/placebo
treatment spatial memory and CBF were evaluated by
Barnes maze and ASL-MRI, respectively (Figure 1).
Mice were sacrificed at 30 or 60 weeks of age, and
tissue was collected for histology and WB (Figure 1).
DABIGATRAN TREATMENT PREVENTS SPATIAL
MEMORY DECLINE IN TgCRND8 AD MICE. Twenty-
five-week-old TgCRND8 AD mice and their WT litter-
mates treated with dabigatran/placebo were tested
with the Barnes maze task to evaluate spatial memory.
During training, all mice showed comparable de-
creases in the latency to explore the escape hole,
indicating a similar acquisition of spatial learning
(Figure 2A). However, during the probe trial, when the
escape hole was blocked and spatial memory retention
was challenged, TgCRND8 AD mice treated with pla-
cebo did not remember where the escape box was and
spent similar time near target and nontarget holes
(Figure 2B). Dabigatran-treated AD mice performed
comparably to WT mice, spending significantly more
time in target than in nontarget areas (Figure 2B),
demonstrating that dabigatran treatment in AD mice
had a beneficial effect on spatial memory retention.
CBF IS PRESERVED IN AD MICE TREATED WITH
DABIGATRAN. ASL-MRI experiments were per-
formed on 40-week-old TgCRND8 and WT mice
treated with dabigatran/placebo to quantify CBF
(Figure 3A). We detected significant cortical hypo-
perfusion in TgCRND8 AD mice, with an w15%
decrease in CBF compared with WT littermates
(Figure 3B) (100.0  4.2% WT/placebo vs. 85.8  3.4%
AD/placebo). This hypoperfusion was prevented by
dabigatran treatment (Figure 3B) (85.8  3.4% AD/
placebo vs. 112.7  9.6% AD/dabigatran).
DABIGATRAN TREATMENT PREVENTS FIBRIN
DEPOSITION IN THE AD BRAIN. We next compared
the amount of insoluble fibrin present in the cortex
and hippocampus of 30- and 60-week-old TgCRND8
and WT mice treated with dabigatran/placebo. WB
assays showed that brain fibrin deposition increased
as mice aged and as AD pathology progressed
(Figure 4) (11). However, after long-term anti-
coagulation with dabigatran, there was less fibrin in
the AD brain (Figure 4), indicating that inhibition of
thrombin prevented pathological fibrin clot formation
































CBF was measured by ASL-MRI in 40-week-old TgCRND8 and WT mice treated with dabigatran/placebo. (A) Anatomic MRI was acquired and
used to delineate the cortical (blue) and thalamic (green) ROIs (top) that were used to measure CBF in the perfusion map (bottom). (B) AD
mice showed a significant decrease in the CBF ratio (cortical CBF/thalamic CBF) compared with WT mice, whereas dabigatran-treated AD mice
presented similar levels of cerebral perfusion as WT mice. The CBF ratio of the WT/placebo group average was considered to be 100%, and
mice from the other groups were represented as relative percentages. Each square or triangle represents an individual mouse. Graph shows
mean  SEM. *p # 0.05, n ¼ 5 to 7 mice/group. CBF ¼ cerebral blood flow; ROI ¼ region of interest; other abbreviations as in Figure 1.
Cortes-Canteli et al. J A C C V O L . 7 4 , N O . 1 5 , 2 0 1 9
Dabigatran Delays Alzheimer’s Disease Pathogenesis O C T O B E R 1 5 , 2 0 1 9 : 1 9 1 0 – 2 3
1914and accumulation in the mouse brain during the
course of the disease.
DABIGATRAN TREATMENT AMELIORATES AMYLOID
BURDEN IN AD MICE. The extent of amyloid pathol-
ogy was measured by immunohistochemistry using
the 6E10 Ab antibody. 6E10 staining showed wide-
spread brain amyloid pathology in 30-week-old
TgCRND8 mice that increased at 60 weeks of age
(Figure 5A). Dabigatran-treated TgCRND8 AD mice
also presented Ab pathology at both ages (Figure 5A),
but quantification showed that the cortical amyloid
burden was significantly ameliorated by w24% in the
60-week-old dabigatran group compared with
placebo-treated mice (Figure 5B) (3.2  0.2% AD/60w/
placebo vs. 2.5  0.2% AD/60w/dabigatran).
We also analyzed whether oligomers, one of the
most toxic species of Ab (31), were also reduced by
dabigatran treatment. Immunostaining using the Ab-
oligomer antibody NAB61 (32) revealed a character-
istic halo of oligomeric staining surrounding amyloidplaques in AD mice (Figure 5C) (33). As expected, the
amount of Ab oligomers increased with age in
TgCRND8 placebo-treated mice, but this increase was
attenuated by 51.8% in dabigatran-treated AD mice
(Figure 5D) (2.1  0.5% AD/60w/placebo vs. 1.0  0.2%
AD/60w/dabigatran). These results provide evidence
that long-term treatment with dabigatran signifi-
cantly decreased amyloid burden and Ab oligomer
pathology in AD mice.
LONG-TERM ANTICOAGULATION WITH DABIGATRAN
DECREASES NEUROINFLAMMATION. AD has a robust
inflammatory component, mainly orchestrated by
microglia and astrocytes (34). CD68 immunohisto-
chemistry showed clusters of phagocytic microglia in
the brains of TgCRND8 mice that increased with age
and pathological progression (Figures 6A and 6B)
(0.5  0.1% AD/30w/placebo vs. 1.3  0.2% AD/
60w/placebo). Anticoagulation reduced neuro-
inflammatory activity as there was a 31% decrease in
cortical CD68 levels in 60-week-old dabigatran-treated
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Fibrin was extracted from the cortex/hippocampus of 30- and 60-week-old TgCRND8 AD and WT mice treated with dabigatran/placebo. (A)
Equal amounts of the fibrin-containing fraction were pooled and subjected to WB using a specific fibrin(ogen) antibody (top), and then
reprobed with a tubulin antibody as loading control (bottom). An in vitro fibrin clot was used as positive control (þ). (B) The amount of the
fibrin b-chain (double arrow in A) and tubulin were quantified in 8 different WBs, averaged, and then plotted. Fibrin content in the brain
increased with age and AD pathology, but dabigatran treatment prevented brain fibrin deposition in 60-week-old AD mice. Graph shows
mean  SEM. Effect of treatment (p < 0.0001) and age (p < 0.0001) are significant. **p # 0.01 AD/60w/placebo versus AD/60w/dabi-
gatran. n ¼ 5 to 11 mice/group. Abbreviations as in Figure 1.
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1915AD mice compared with placebo (Figures 6A and 6B)
(1.3  0.2% AD/60w/placebo vs. 0.9  0.1% AD/60w/
dabigatran). We next analyzed whether AD-related
astrogliosis was also ameliorated by long-term anti-
coagulation. WB assays showed that the overall
levels of 2 markers elevated in reactive astrocytes,
vimentin and glial fibrillary acidic protein (GFAP),
were significantly decreased by 50% and 32.3%,
respectively, in TgCRND8 60-week-old dabigatran-
treated mice compared with placebo (Figures 6C
and 6D).
Neuroinflammation in AD is also characterized
by infiltration of peripheral T cells into the brain (35).
We detected an increase in CD3-positive cellsinside the brains of TgCRND8 mice compared with
nontransgenic controls, and this number was
augmented during pathological progression with age
(Figures 6E and 6F) (1.3  0.3 CD3þ cells/mm2 AD/30w/
placebo vs. 8.2  1.2 CD3þ cells/mm2 AD/60w/
placebo). The majority of CD3-positive cells were
extravasated into the brain parenchyma (Figure 6G),
and this recruitment to the brain was decreased by
30% in aged AD mice treated with dabigatran
(Figures 6E and 6F) (8.2  1.2 CD3þ cells/mm2 AD/60w/
placebo vs. 5.6  0.7 CD3þ cells/mm2 AD/60w/
dabigatran). All these results demonstrate that long-
term anticoagulation with dabigatran ameliorated
AD-related neuroinflammation.




















































AD + Placebo AD + Dabigatran
Ab brain pathology was analyzed in TgCRND8 and WT mice treated with dabigatran (dab)/placebo (plac). (A) Ab immunohistochemistry (6E10) showed widespread
amyloid pathology throughout the brains of 30- and 60-week-old TgCRND8 AD mice (insets show higher magnification of cortical amyloid plaques). Sections and
quantified cortical areas are outlined for clarity. (B) The 6E10-positive cortical area was decreased by 23.7% in 60-week-old dabigatran-treated TgCRND8 mice
compared with placebo. (C) Ab oligomer immunofluorescence analysis (NAB61 [green]) showed staining around fibrillar amyloid plaques (Congo Red [red]) in the
brains of TgCRND8 mice (see insets for higher magnification). Confocal tile-scan Z-stacks were acquired over the parietal cortex, and quantification of the NAB61-
positive area showed dabigatran treatment decreased by 51.8% the amount of oligomeric Ab in the cortex of 60-week-old AD mice (D). Graphs show mean  SEM.
Effect of treatment (p ¼ 0.0089 for 6E10 and p ¼ 0.0083 for NAB61) and age (p < 0.0001 for both) are significant. *p # 0.05, **p # 0.01 AD/60w/placebo versus
AD/60w/dabigatran. n ¼ 5 to 11 mice/group. Abbreviations as in Figure 1.
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FIGURE 6 Dabigatran Treatment Ameliorated Neuroinflammation in AD Mice
A E















































































































(A) Immunohistochemical analysis showed CD68-positive microglial clusters in 30-week-old and more numerously in 60-week-old AD mice. (B) Quantification of the
CD68-positive cortical area showed a 31.3% decrease in the amount of phagocytic microglia in 60-week-old dabigatran-treated AD mice compared to placebo. (C)
Soluble proteins from 60-week-old mice were extracted, pooled, and subjected to WB using a vimentin antibody (top), and then reprobed with a GFAP antibody
(middle) and a tubulin antibody (loading control, bottom). Six different WBs were quantified, averaged, and plotted (D). Degradation products of vimentin and GFAP
astrocytic markers drastically increased in AD mice compared with WT mice (53), but their levels were ameliorated in dabigatran-treated AD mice by 50% and 32.3%,
respectively. (E) Immunohistochemical staining showed scattered CD3-positive cells in 30-week-old AD brains that increased with age and pathology. (F) Quantifi-
cation of CD3-positive cells in the cortex showed that infiltrated T cells significantly decreased by 32.2% in dabigatran-treated AD mice compared with placebo. (G)
Double immunofluorescence showed that CD3-positive cells (red) were not inside blood vessels (CD31, green) but rather were extravasated into the brain parenchyma.
(B and F) The cortical area quantified was similar to the one outlined in the low-power images in Figure 5A. Graphs show mean  SEM. The effect of treatment and
age were significant (p < 0.0001 for both). *p # 0.05, **p # 0.01, ***p # 0.001 AD/60w/placebo versus AD/60w/dabigatran. n ¼ 5 to 11 mice/group (A to F) and
n ¼ 5 to 6 mice/group (C and D). GFAP ¼ glial fibrillary acidic protein; other abbreviations as in Figures 1 and 5.
J A C C V O L . 7 4 , N O . 1 5 , 2 0 1 9 Cortes-Canteli et al.
O C T O B E R 1 5 , 2 0 1 9 : 1 9 1 0 – 2 3 Dabigatran Delays Alzheimer’s Disease Pathogenesis
1917













































































Continued on the next page
Cortes-Canteli et al. J A C C V O L . 7 4 , N O . 1 5 , 2 0 1 9
Dabigatran Delays Alzheimer’s Disease Pathogenesis O C T O B E R 1 5 , 2 0 1 9 : 1 9 1 0 – 2 3
1918
J A C C V O L . 7 4 , N O . 1 5 , 2 0 1 9 Cortes-Canteli et al.
O C T O B E R 1 5 , 2 0 1 9 : 1 9 1 0 – 2 3 Dabigatran Delays Alzheimer’s Disease Pathogenesis
1919DABIGATRAN TREATMENT PRESERVED BBB
INTEGRITY IN AD MICE. We next analyzed the
expression and localization of aquaporin 4 (AQP4), a
water channel selectively present in astrocytic peri-
vascular endfeet and essential for Ab clearance and
neurovascular coupling (36). AQP4 was localized
around brain blood vessels in 60-week-old WT mice
(Figures 7A and 7B). However, in age-matched AD
mice, astrocyte depolarization was found with
AQP4 expression shifting from the astrocytic endfeet
surrounding vessels to areas of neuropil near the
amyloid plaques (Figure 7A). Quantification showed
that perivascular AQP4 decreased by 30% in AD mice
compared with age-matched WT controls (Figure 7C)
(100.0  5.6% WT/60w/placebo vs. 67.4  2.5%
AD/60w/placebo). Dabigatran treatment partially
prevented the redistribution of AQP4 expression from
endfeet to non-endfeet areas in AD mice (Figure 7C)
(67.4  2.5% AD/60w/placebo vs. 88.0  3.3% AD/
60w/dabigatran).
Because pericytes are also an integral part of
the neurovascular unit, we performed immunohisto-
chemical analysis using the pericyte marker platelet-
derived growth factor receptor-b (PDGFRb). We
observed that pericytes in the TgCRND8 AD mice pre-
sented abnormal hypertrophic processes surrounding
capillaries (Figure 7D), similar to what has been
described in other transgenic AD mouse lines (37).
These elongated processes significantly increased the
overall PDGFRb-positive area in the cortex of 60-week-
old AD mice compared with WT littermates (Figure 7E)
(0.11  0.006% WT/60w/placebo vs. 0.18  0.02% AD/
60w/placebo). Dabigatran treatment ameliorated
these alterations in pericyte morphology and normal-
ized the PDGFRb staining in TgCRND8 AD mice
(Figures 7D and 7E) (0.18  0.02% AD/60w/placebo vs.
0.08  0.02% AD/60w/dabigatran).
Taken together, our results indicate that the
beneficial effects observed after long-term anti-
coagulation with dabigatran could be partially due to
improved preservation of BBB structure and
integrity.FIGURE 7 Continued
Immunostaining was performed on brain slices from 60-week-old TgCRN
AQP4 and PDGFRb. (A) Double immunofluorescence showed that AQP4
WT mice. However, AQP4 staining shifted from its perivascular location
analysis was performed to segment and quantify the amount of perivascu
significantly more perivascular AQP4 staining than placebo-treated AD m
outlining the capillaries of TgCRND8 AD mice. (E) Quantification showed
with WT mice. This abnormal pericyte staining was normalized by dabiga
AQP4 ¼ aquaporin 4; PDGFRb ¼ platelet-derived growth factor receptoDISCUSSION
Increasing evidence supports a chronic procoagulant
state in AD with important implications for disease
onset and progression. Here, we present behavioral,
physiological, and molecular evidence that targeting
the thrombotic component of this disorder with a
DOAC ameliorates different AD pathological hall-
marks in an AD mouse model (Central Illustration).
Treatment with dabigatran preserved cerebral perfu-
sion and prevented memory decline in TgCRND8
AD mice. These functional improvements were
accompanied in the long term by inhibition of fibrin
deposition, amelioration of amyloid burden and
neuroinflammatory activity, and enhanced preserva-
tion of the BBB in the AD mouse brain.
Pathological accumulation of cerebral fibrin in the
brain parenchyma and inside cerebral blood vessels
plays a role on AD pathogenesis (10,11,38). Dabigatran
treatment prevented the abnormal deposition of fibrin
(Figure 4), which may have facilitated the cerebral
circulation in the ADmouse brain (Figure 3). This result
is remarkable because CBF alterations precede the
onset of dementia (39). Additionally, long-term anti-
coagulation decreased amyloid plaques, and, more
importantly, halved levels of Ab oligomers (Figure 5),
the toxic Ab species recognized as a main contributor
to AD synaptic dysfunction (31). Because Ab strongly
interacts with fibrin (15) and fibrinogen (13), and this
interaction induces formation of blood clots resistant
to degradation (10,15), decreasing the amount of fibrin
by long-term anticoagulation may have prevented Ab
binding and subsequent entrapment into degradation-
resistant clots.
Hemostatic and nonhemostatic mechanisms were
likely involved in dabigatran’s amelioration of AD
neuroinflammation (Figure 6). Reduction in fibrin clot
formation, and the subsequent improvement in CBF,
may have allowed proper nutrient and oxygen
delivery to the brain, supporting neural health
and function. In addition, dabigatran also inhibits
thrombin’s effect on platelet aggregation (23), henceD8 AD and WT mice treated with dabigatran/placebo to detect expression and localization of
expression (red) was found around blood vessels (CD31 [green]) in the astrocytic endfeet of
to neuropil areas surrounding amyloid plaques in AD mice (arrows). (B) Immunohistochemical
lar AQP4 in all experimental groups (C). AD mice treated long term with dabigatran presented
ice. (D) PDGFRb immunohistochemistry demonstrated hypertrophic pericytic processes
a robust increase of PDGFRb-positive area in the cortex of 60-week-old AD mice compared
tran treatment. Graphs show mean  SEM. **p # 0.01, ***p # 0.001. n ¼ 5 to 6 mice/group.
r-b; other abbreviations as in Figures 1 and 5.
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1920contributing to decrease primary hemostasis and
recruitment of white blood cells into the AD brain.
Furthermore, thrombin, fibrin, and Ab act as proin-
flammatory mediators in AD (9,34,40,41). Therefore,
the inhibition of thrombin and the resulting decrease
in fibrin and Ab accumulation in the dabigatran-
treated AD mice possibly contributed to the amelio-
ration of neuroinflammation. Studies using other AD
mouse models have shown that thrombin inhibition
diminishes the neuroinflammatory response (40,42),
further supporting the role of thrombin in AD-related
inflammation.
The BBB is compromised in AD, which translates
into neurovascular uncoupling (6), together with
leakage of plasma components (e.g., thrombin and
fibrin) into the cerebral parenchyma, failure of proper
elimination of waste products (e.g., Ab), and infiltra-
tion of peripheral immune cells into the brain (5).
Long-term anticoagulation with dabigatran amelio-
rated all of these pathological features, possibly
through preservation of pericytes and astrocytic
endfeet, integral parts of the neurovascular unit
(Figure 7). Dabigatran specifically prevented the
redistribution of perivascular AQP4, one of the key
players in the uptake, clearance, and active transport
of Ab through the BBB (36), which may have facili-
tated Ab drainage and contributed to the decrease in
amyloid burden (Figure 5). Dabigatran treatment also
prevented pericyte alterations in the AD mouse brain.
Considering that pericyte degeneration in AD con-
tributes to BBB disruption (43), fibrin extravasation
(44), and depolarization of astrocyte endfeet (45),
preservation of pericyte structure and/or function by
dabigatran may have contributed to the observed
reduction in fibrin content in the AD brain (Figure 4)
and the maintenance of AQP4 at astrocytic endfeet
(Figure 7). The imbalance between Ab production and
clearance through an impaired BBB is considered one
of the main pathological processes underlying AD (1).
Our results further support the hypothesis that fibrin
and altered hemostasis may be one of the missing
links between AD and vascular pathology (8,17).
The amelioration of AD-related neuro-
inflammation, amyloid burden, and BBB dysfunction
was observed to be significant only after long-term
anticoagulation. Because the procoagulant state in
AD is a chronic, sustained process, and fibrin depo-
sition accumulates in the brain as pathology advances
with age (Figure 4 and Cortes-Canteli et al. [11]), the
effect of dabigatran treatment was more robust after
longstanding treatment. Indeed, recent epidemio-
logical studies have shown reduced incidence of
dementia in atrial fibrillation patients that undergo
long-term anticoagulation (46). Interestingly, we alsoobserved that treatment with dabigatran was accom-
panied by preservation of cognition (Figure 2), which
is essential for any molecule to be considered a
promising therapeutic approach in AD.
Our results indicate that the normalization of the
AD prothrombotic state with dabigatran ameliorated
AD pathogenesis. We expect that other clinically
approved DOACs, such as factor Xa inhibitors, may
have a similar beneficial effect on AD. Repurposing an
already approved drug, such as a DOAC, to a new
disease indication, such as AD, translates to a quicker
transition from bench to bedside and a greater clinical
impact.
AD is a multifactorial disease, and efforts should be
focused toward the development of multidrug
personalized therapies targeting the different mech-
anisms contributing to an individual’s pathology
instead of the “1 target, 1 treatment” approach that
has not been successful thus far. Our studies indicate
that a pathological mechanism worth targeting in AD
is the procoagulant state, although other contributing
factors should be also treated accordingly.
STUDY LIMITATIONS. One of the limitations of anti-
coagulation in AD is the increased incidence of
intracerebral hemorrhage in AD patients due to the
presence of cerebral microbleeds (47) and Ab depo-
sition in vessels as cerebral amyloid angiopathy (CAA)
(48). The incidence of both of these vasculopathies is
also linked with worse cognitive performance, and
the appropriate use of antithrombotic agents in this
population is under debate (49). Dabigatran presents
a low risk of intracranial bleeding (24,25) and does not
promote the formation of cerebral microbleeds in AD
mice (50). Furthermore, we observed no hemorrhages
or incidents of intracerebral bleeding in any of our
animals (data not shown). Nevertheless, use of dabi-
gatran or other antithrombotic agents in AD patients
with widespread CAA and cerebral microbleeds will
need to be carefully evaluated by a heart–brain team
of experts to ensure its use outweighs any bleeding
risk (49). Yet, if dabigatran is used early in the course
of the disease, Ab may be cleared more efficiently
through the BBB, hence decreasing its deposition in
the cortical and leptomeningeal vessels forming CAA.
Also, because increased clot formation in AD is
a chronic process, long-term treatment with low
doses of dabigatran may be sufficient to have a ther-
apeutic effect in AD. The dose used in the present
study is lower than what has been used in other
animal studies (26,42,51). Because the half-life of
dabigatran etexilate in mice is short (w15 min) and
dabigatran is 2-fold less effective inhibiting mouse
than human thrombin (23), a supratherapeutic dose
in mice is needed to achieve similar plasma
CENTRAL ILLUSTRATION Dabigatran Treatment Ameliorates Alzheimer’s Disease Pathogenesis in the
TgCRND8 Mouse Model
Cortes-Canteli, M. et al. J Am Coll Cardiol. 2019;74(15):1910–23.
Long-term treatment with dabigatran prevents fibrin deposition in the Alzheimer’s disease brain, ameliorating amyloid pathology and neuroinflammation and
preserving blood–brain barrier integrity and central blood flow. Ab ¼ amyloid-b; BBB ¼ blood–brain barrier.
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1922concentrations of the drug as in humans. Although
further studies are required to carefully extrapolate
the long-term anticoagulation achieved in our AD
mice to humans, the dose we used rendered plasma
dabigatran concentrations similar to what has been
reported in patients undergoing long-term anti-
coagulation (52). Additionally, even though dabiga-
tran presents a predictable pharmacokinetic profile
(22), long-term anticoagulation in the frail, aging,
and comorbid AD population may benefit from a
drug-tailored program.PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AD
has a multifactorial etiology, and thrombosis is among
the mechanisms involved. In a transgenic mouse
model of AD, long-term anticoagulation with dabiga-
tran reduced fibrin deposition, neuroinflammation,
amyloid deposition, and cognitive decline.
TRANSLATIONAL OUTLOOK: Concordant results
of additional studies in other animal models would
support clinical trials of antithrombotic therapy for
prevention or amelioration of AD.CONCLUSIONS
Long-term anticoagulation with dabigatran inhibits
thrombin and the abnormal deposition of fibrin in the
AD brain, hence preserving blood flow and facilitating
oxygen and nutrient delivery to the brain. This drug,
in turn, has a beneficial effect on controlling neuro-
inflammation, maintaining the integrity and func-
tionality of the BBB, and facilitating Ab clearance
(Central Illustration). Therefore, therapeutics aimed at
normalizing the prothrombotic environment present
in AD, in combination with other disease-modifying
compounds, might be instrumental in improving AD
pathogenesis.
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